JP2017536421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536421A5 JP2017536421A5 JP2017547930A JP2017547930A JP2017536421A5 JP 2017536421 A5 JP2017536421 A5 JP 2017536421A5 JP 2017547930 A JP2017547930 A JP 2017547930A JP 2017547930 A JP2017547930 A JP 2017547930A JP 2017536421 A5 JP2017536421 A5 JP 2017536421A5
- Authority
- JP
- Japan
- Prior art keywords
- release composition
- migraine
- sustained release
- subject
- sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 62
- 208000019695 Migraine disease Diseases 0.000 claims description 42
- 206010027599 migraine Diseases 0.000 claims description 42
- 238000013268 sustained release Methods 0.000 claims description 37
- 239000012730 sustained-release form Substances 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 17
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims description 16
- 230000036470 plasma concentration Effects 0.000 claims description 13
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 12
- 229960000991 ketoprofen Drugs 0.000 claims description 12
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 12
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 12
- -1 exercise Substances 0.000 claims description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 239000001961 anticonvulsive agent Substances 0.000 claims description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims description 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000001815 facial effect Effects 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 210000001738 temporomandibular joint Anatomy 0.000 claims description 4
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical class [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 claims description 3
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 3
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 230000003556 anti-epileptic effect Effects 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 229960003965 antiepileptics Drugs 0.000 claims description 3
- 239000002249 anxiolytic agent Substances 0.000 claims description 3
- 230000000949 anxiolytic effect Effects 0.000 claims description 3
- 229960000590 celecoxib Drugs 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 3
- 229960000616 diflunisal Drugs 0.000 claims description 3
- 208000002173 dizziness Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 229960005293 etodolac Drugs 0.000 claims description 3
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001419 fenoprofen Drugs 0.000 claims description 3
- 229960002390 flurbiprofen Drugs 0.000 claims description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 229940013798 meclofenamate Drugs 0.000 claims description 3
- 229960003464 mefenamic acid Drugs 0.000 claims description 3
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 3
- 229960001929 meloxicam Drugs 0.000 claims description 3
- 239000003158 myorelaxant agent Substances 0.000 claims description 3
- 229960004270 nabumetone Drugs 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 229960002739 oxaprozin Drugs 0.000 claims description 3
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 229960002702 piroxicam Drugs 0.000 claims description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960000371 rofecoxib Drugs 0.000 claims description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 3
- 229960000953 salsalate Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 229960000894 sulindac Drugs 0.000 claims description 3
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229960002004 valdecoxib Drugs 0.000 claims description 3
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010014020 Ear pain Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 241001539473 Euphoria Species 0.000 claims description 2
- 206010015535 Euphoric mood Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 206010028735 Nasal congestion Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 206010028836 Neck pain Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010033474 Pain of skin Diseases 0.000 claims description 2
- 206010033546 Pallor Diseases 0.000 claims description 2
- 208000004880 Polyuria Diseases 0.000 claims description 2
- 208000007613 Shoulder Pain Diseases 0.000 claims description 2
- 206010042682 Swelling face Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 206010006514 bruxism Diseases 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 230000004313 glare Effects 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 210000004373 mandible Anatomy 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 229940127234 oral contraceptive Drugs 0.000 claims description 2
- 239000003539 oral contraceptive agent Substances 0.000 claims description 2
- 230000008447 perception Effects 0.000 claims description 2
- 210000004761 scalp Anatomy 0.000 claims description 2
- 208000018316 severe headache Diseases 0.000 claims description 2
- 230000035900 sweating Effects 0.000 claims description 2
- 230000002123 temporal effect Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 206010048961 Localised oedema Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 229960001017 tolmetin Drugs 0.000 claims 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
- 229960002688 choline salicylate Drugs 0.000 description 2
- 229940072082 magnesium salicylate Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 208000015004 muscle tenderness Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462085943P | 2014-12-01 | 2014-12-01 | |
| US62/085,943 | 2014-12-01 | ||
| PCT/US2015/063220 WO2016089893A1 (en) | 2014-12-01 | 2015-12-01 | Methods and compositions for treating migraine and conditions associated with pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001791A Division JP2020073563A (ja) | 2014-12-01 | 2020-01-09 | 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536421A JP2017536421A (ja) | 2017-12-07 |
| JP2017536421A5 true JP2017536421A5 (https=) | 2019-01-17 |
Family
ID=56092337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547930A Pending JP2017536421A (ja) | 2014-12-01 | 2015-12-01 | 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 |
| JP2020001791A Pending JP2020073563A (ja) | 2014-12-01 | 2020-01-09 | 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001791A Pending JP2020073563A (ja) | 2014-12-01 | 2020-01-09 | 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20170266106A1 (https=) |
| EP (1) | EP3226972A4 (https=) |
| JP (2) | JP2017536421A (https=) |
| CN (1) | CN107614061A (https=) |
| CA (1) | CA3006962A1 (https=) |
| WO (1) | WO2016089893A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789343A (zh) * | 2017-11-08 | 2018-03-13 | 莫玉艳 | 一种治疗偏头痛的药物及其制备方法 |
| CA3119728A1 (en) | 2018-11-21 | 2020-05-28 | Tremeau Pharmaceuticals, Inc. | Purified forms of rofecoxib, methods of manufacture and use |
| JP2022521020A (ja) * | 2019-02-22 | 2022-04-04 | ペア セラピューティクス インコーポレイテッド | 偏頭痛に関連付けられた症状の処置のためのシステム及び方法 |
| CN110432888B (zh) * | 2019-08-15 | 2021-11-23 | 任鹏宇 | 一种前庭神经权重信息编码神经元的筛选方法 |
| US10945992B1 (en) * | 2019-11-13 | 2021-03-16 | Tremeau Pharmaceuticals, Inc. | Dosage forms of rofecoxib and related methods |
| KR20230051117A (ko) * | 2020-01-10 | 2023-04-17 | 브리오리 바이오테크 인코포레이티드 | 로페콕시브를 함유하는 국소 조성물 및 이의 제조 및 사용 방법 |
| EP3900715A1 (en) * | 2020-04-21 | 2021-10-27 | Dompe' Farmaceutici S.P.A. | Synergistic admixtures of gabapentin and ketoprofen, pharmaceutical compositions and their medical use |
| WO2022147155A1 (en) * | 2020-12-31 | 2022-07-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| IL310680A (en) * | 2021-08-16 | 2024-04-01 | Cerecin Inc | Methods for the treatment of migraine and related headache symptoms using tricaprylin |
| AU2023385700A1 (en) * | 2022-11-23 | 2025-07-10 | Medicon Pharmaceuticals, Inc. | Treating pain associated with central sensitization |
| CN115998724B (zh) * | 2023-03-28 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 布洛芬在抗幻觉作用药物中的新用途 |
| WO2025111078A1 (en) * | 2023-11-21 | 2025-05-30 | Medicon Pharmaceuticals, Inc. | Oral administration of compounds for treating pain |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3759980A (en) * | 1969-05-26 | 1973-09-18 | Stockton Chemicals Inc | Salicylates |
| US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
| US5169637A (en) | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| CA1237671A (en) | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
| JPS60155111A (ja) * | 1983-10-20 | 1985-08-15 | Hisamitsu Pharmaceut Co Inc | 安定なケトプロフェン含有外用経皮製剤 |
| US4532244A (en) * | 1984-09-06 | 1985-07-30 | Innes Margaret N | Method of treating migraine headaches |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| US5409704A (en) | 1985-06-26 | 1995-04-25 | The Liposome Company, Inc. | Liposomes comprising aminoglycoside phosphates and methods of production and use |
| US5023087A (en) | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| US5032582A (en) | 1987-02-27 | 1991-07-16 | Liposome Technology, Inc. | Method for treating fungal infections with amphotericin B/cholesterol sulfate composition |
| US4994213A (en) | 1988-05-17 | 1991-02-19 | Liposome Technology, Inc. | Method of preparing lipid structures |
| US5082866A (en) | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
| US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
| US5194266A (en) | 1989-08-08 | 1993-03-16 | Liposome Technology, Inc. | Amphotericin B/cholesterol sulfate composition and method |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| DE69211691T2 (de) | 1991-04-19 | 1997-01-16 | Nexstar Pharmaceuticals Inc., Boulder, Col. | Pharmazeutische formulierung und pharmazeutisches verfahren |
| HU223343B1 (hu) | 1991-05-20 | 2004-06-28 | Novartis Ag. | Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására |
| GR1002207B (en) | 1992-08-06 | 1996-03-27 | Johnson & Johnson Consumer | Skin care compositions containing imidazoles. |
| US5552155A (en) | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
| AU5938996A (en) | 1995-06-07 | 1996-12-30 | Nexstar Pharmaceuticals, Inc. | Method for encapsulating pharmaceutical materials |
| US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
| US6387407B1 (en) | 1995-09-29 | 2002-05-14 | L.A.M. Pharmaceutical Corporation | Topical drug preparations |
| US5667799A (en) | 1995-10-30 | 1997-09-16 | Caldwell; Larry J. | Method for treating headache pain with topical local anesthetic compositions |
| CN1102852C (zh) | 1995-11-13 | 2003-03-12 | 皮特迈国际有限公司 | 含一氧化二氮的止痛药、消炎药和解热药的给药介质及含有这样的介质和药物的药物组合物 |
| US5914129A (en) * | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| US6083996A (en) | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
| US6090368A (en) | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
| US6139861A (en) | 1999-01-14 | 2000-10-31 | Friedman; Mark | Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm |
| US6118020A (en) | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| US6642243B1 (en) | 1999-07-22 | 2003-11-04 | Ashkan Imanzahrai | Migraine medicine and method for treating same |
| US6896898B1 (en) * | 1999-11-19 | 2005-05-24 | Xel Herbaceuticals, Inc. | Transdermal delivery system for alkaloids of aconitum species |
| US20020143047A1 (en) | 2001-01-05 | 2002-10-03 | Galer Bradley S. | Methods for treating indomethacin responsive headaches |
| US20070112052A9 (en) * | 2001-01-05 | 2007-05-17 | Larry Caldwell | Methods and compositions for treating headache pain with topical NSAID compositions |
| DK1435945T3 (da) * | 2001-06-05 | 2008-12-01 | Ronald Aung-Din | Topisk migræne terapi |
| US20040138239A1 (en) * | 2001-08-23 | 2004-07-15 | Bruce Frome | Compositions and methods for targeting cerebral circulation and treatment of headache |
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| WO2004075832A2 (en) | 2003-02-27 | 2004-09-10 | Lucas John M | Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof |
| US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
| US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
| US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
| US20050019354A1 (en) | 2003-07-23 | 2005-01-27 | Perricone Nicholas V. | Topical benfotiamine treatments |
| CA2536096A1 (en) | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
| WO2005102307A2 (en) | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
| US20090214466A1 (en) | 2005-05-09 | 2009-08-27 | Levin Bruce H | Methods of Alleviating Disorders and Their Associated Pain |
| CA2620202C (en) * | 2005-08-26 | 2016-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| WO2007061694A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin tricyclic cgrp receptor antagonists |
| US20090312435A1 (en) | 2006-08-30 | 2009-12-17 | Auspex Pharmaceuticals, Inc | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
| US20080317684A1 (en) | 2006-09-06 | 2008-12-25 | Isw Group, Inc. | Topical Compositions |
| WO2008054788A2 (en) * | 2006-10-31 | 2008-05-08 | Chrono Therapeutics, Inc. | Transdermal delivery techniques for drugs, nutraceuticals and other active substances |
| SG10201406930UA (en) | 2009-07-27 | 2014-11-27 | Nocicepta Llc | Methods For Treatment Of Pain |
| EP2512460A4 (en) | 2009-12-18 | 2015-01-21 | Exodos Life Sciences Ltd Partnership | METHOD AND COMPOSITIONS FOR STABLE LIQUID ACTIVE FORMULATIONS |
| WO2011075654A1 (en) | 2009-12-18 | 2011-06-23 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating inflammation of skin |
| WO2011075688A1 (en) | 2009-12-18 | 2011-06-23 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions |
| AU2010330813B2 (en) | 2009-12-18 | 2016-04-28 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating peripheral vascular disease |
| US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
| US9681837B2 (en) | 2012-02-20 | 2017-06-20 | Keio University | Central sensitization diagnosis device and method for operating same |
| US8491917B1 (en) * | 2012-03-12 | 2013-07-23 | William J. Bender | Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head |
| US8822537B2 (en) * | 2012-09-27 | 2014-09-02 | Achelios Therapeutics, Inc. | Topical ketoprofen composition |
| EA030797B1 (ru) | 2012-12-21 | 2018-09-28 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Система трансдермальной доставки гормонов (варианты) и способы ее применения |
| WO2017106714A1 (en) | 2015-12-16 | 2017-06-22 | Achelios Therapeutics, Inc. | Methods and compositions for treating peripheral neuropathy |
-
2015
- 2015-12-01 EP EP15864857.6A patent/EP3226972A4/en not_active Withdrawn
- 2015-12-01 WO PCT/US2015/063220 patent/WO2016089893A1/en not_active Ceased
- 2015-12-01 US US15/532,425 patent/US20170266106A1/en not_active Abandoned
- 2015-12-01 CA CA3006962A patent/CA3006962A1/en not_active Abandoned
- 2015-12-01 CN CN201580075227.5A patent/CN107614061A/zh active Pending
- 2015-12-01 JP JP2017547930A patent/JP2017536421A/ja active Pending
-
2018
- 2018-12-27 US US16/234,069 patent/US11026882B2/en active Active
-
2020
- 2020-01-09 JP JP2020001791A patent/JP2020073563A/ja active Pending
-
2021
- 2021-06-07 US US17/341,029 patent/US20220125712A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536421A5 (https=) | ||
| Rascol et al. | New treatments for levodopa‐induced motor complications | |
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| JP6200648B2 (ja) | 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための組成物 | |
| JP2013544850A5 (https=) | ||
| JP2020073563A (ja) | 片頭痛及び疼痛に関連する状態を処置するための方法及び組成物 | |
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| Staud | Pharmacological treatment of fibromyalgia syndrome: new developments | |
| CA2926389A1 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| BRPI0414347A (pt) | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade | |
| TW202435860A (zh) | 用於治療疼痛的ｒ—ｍｄｍａ | |
| JP2016505050A5 (https=) | ||
| JP2005519936A5 (https=) | ||
| Velling et al. | Sustained-release niacin for prevention of migraine headache | |
| Bug et al. | Phase I/II study of BI 6727 (volasertib), an intravenous polo-like kinase-1 (Plk1) inhibitor, in patients with acute myeloid leukemia (AML): results of the dose finding for BI 6727 in combination with low-dose cytarabine | |
| CN106413714A (zh) | (r)‑吡吲哚及其药学上可接受的盐的药学用途 | |
| TW202448458A (zh) | 雌激素受體降解劑與ａｋｔ抑制劑之組合 | |
| Cox | Pharmacology interventions for symptom management | |
| Calandrella et al. | Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease | |
| RS61481B1 (sr) | Lečenje migrene acetil-leucinom | |
| WO2004032844A2 (en) | Compositions and methods for treating pain | |
| Romeyke et al. | Integration of Cannabis Extract Tetrahydrocannabinol: Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder | |
| Karabin et al. | The recent guidelines for pharmacotherapy of Parkinson’s Disease | |
| JP2007513095A5 (https=) | ||
| Patel et al. | Migraine-Recent Developments and Future Opportunities |